Fosun Pharma raises $512 million, while Dynasty Reit cancels IPO
The market remains challenging for new listings and both deals attract modest demand from international investors, with Fosun forced to reallocate shares to retail investors to make up for the lack of institutional interest.
October 25, 2012
.jpg&h=171&w=304&q=75&v=7c07f1e36c&c=1)
